Amarantus Bioscience Holdings Inc (AMBS)

[Old Hillbilly]

The "recantation" was already made silly. There are a lot of grants made by MJFF that the conclusions have not been officially published.
You need to recant your statement"

and statement that they have no interest in funding AMBS.

The MJFF has never made such a statement! That they have "no Interest in funding AMBS"
Why you would say that is questionable!
What the did en FACT say was

Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Share with Twitter Share with LinkedIn
Share with Repost.us

SUNNYVALE, Calif., Nov. 7, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today updated shareholders on the timing of the final data set from its grant from the Michael J. Fox Foundation being released to the marketplace. The Company expects to have the data set available in December. Upon completion of the data analysis correlate of the positive behavioural animal data for MANF previously reported with histology data confirming re-innervation of the striatum due to MANF delivery to the substantia nigra, the Michael J. Fox Foundation will consider funding additional studies to advance MANF as a disease-modifying treatment for Parkinson's disease.
http://www.prnewswire.com/news-releases/amarantus-biosciences-updates-shareholders-on-timing-of-michael-j-fox-foundation-grant-data-release-177625521.html

The correction:

Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release



SUNNYVALE, Calif. – CORRECTED November 8, 2012 –

Amarantus BioSciences, Inc. (OTCQB: AMBS) is issuing corrections to a press release dated November 7 regarding data from a study into MANF, funded by The Michael J. Fox Foundation (MJFF).



To clarify remarks in the original release, MJFF does not agree with Amarantus’ statements that, to-date, reported behavioural pre-clinical data were positive, and that histology data confirm re-innervation of the striatum due to MANF delivery. MJFF reserves any view on the histology results until the final data are available. In addition, MJFF is not considering additional funding to Amarantus at this time. Amarantus has announced the final data will be available in December.



MJFF continues to invest in promising neurotrophic factor approaches, and will apply takeaways from this study to future initiatives. The Foundation still believes that MANF is a potentially promising trophic factor.



A link to the original release is below.

http://www.prnewswire.com/news-releases/amarantus-biosciences-updates-shareholders-on-timing-of-michael-j-fox-foundation-grant-data-release-177625521.html
About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
http://www.sec.gov/Archives/edgar/data/1424812/000114420412070094/v330915_ex99-1.htm

Again this thread is continue here:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=88250742

We all also know you have no e-mail from the MJFF stating no jnterest in MANF or AMBS.